Lophora Submits Clinical Trial Authorisation (CTA) Application to the French Medicines Agency (ANSM) for lead CNS drug LPH-5.

Lophora Liber herbarium

Lophora, a clinical-stage CNS drug discovery company developing novel, next generation 5HT2ARA medicines to treat a multitude of psychiatric disorders, announced today that it has submitted a Clinical Trial Application (CTA) for its lead drug program LPH-5. The CTA is directed towards a Phase I first-in-human study to assess the safety, tolerability, pharmacokinetics and potential […]

Lophora Closes Bridge Round to Strengthen Global Patent Portfolio and prepare for Phase I

Lophora White flowers

Founded by initial investments from BII (Novo Nordisk Foundation), Vækstfonden (EIFO) and Innovation Fund Denmark, Lophora has received additional support of ~US$1M from a syndicate of family offices and experienced biotech investors. The new investment allows Lophora to strengthen its global composition of matter patent portfolio and produce GMP-grade drug product of its first-in-class lead candidate LPH-5, which is ready to enter Phase I studies.

Lophora Receives Additional Funding to Complete Pre-Clinical Development of LPH-5 – A Novel and Innovative Agent to Address Treatment-Resistant Depression

Lophora Alhambra wall

Founded by an initial investment of US$1.8M from the BioInnovation Institute (a Novo Nordisk Foundation Initiative), Lophora has received additional support of US$1.6M from The Danish Growth Fund (Vækstfonden) and the Danish Innovation Fund (Innovationsfonden), allowing Lop hora to complete pre-clinical development of its first-in-class lead candidate LPH-5, which is expected to enter Phase I studies in early 2022.

Lophora Initiates Preclinical Development of LPH-5 for Treatment-Resistant Depression

Lophora has been granted a $1.5M convertible loan by the Novo Nordisk Foundation to advance their first-in-class lead candidate LPH-5.
In early 2020, Lophora was successfully accepted into the Creation House program at BioInnovation Institute and granted a $1.5M convertible loan by the Novo Nordisk Foundation.
Lophora will now advance their lead candidate LPH-5 through pre-clinical development in order to de-risk the compound prior to the initiation of first-in-human studies towards the end of 2021. Amongst other things, this involves the large-scale production of LPH-5, followed by a detailed characterization of the molecule’s safety profile, which is a key regulatory requirement prior to initiating clinical studies.